Results 201 to 210 of about 91,755 (270)

Unraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma

open access: yesInternational Journal of Cancer, Volume 159, Issue 11, Page 2824-2834, 1 December 2026.
ABSTRACT Despite substantial clinical benefit from immune checkpoint inhibitors (ICI), advanced melanoma remains challenging due to frequent treatment resistance. Resistance may be intrinsic (primary) or emerge over time (secondary). Biomarkers predicting distinct resistance phenotypes before therapy are lacking.
Julian Kött   +17 more
wiley   +1 more source

The Place of Therapeutic Apheresis in Severe Immune‐Related Adverse Events: A Scoping Review of Literature

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 6, December 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet   +36 more
wiley   +1 more source

The Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications

open access: yesMedComm, Volume 7, Issue 12, December 2026.
1. This paper proposes the “oncobiome” as a unifying conceptual framework that integrates commensal, pathobiont, and tumor‐resident microbes into a coherent biological processor driving malignancy. 2. This study describes the dynamic shift from a homeostatic microbiome to a pathological oncobiome, detailing how diet, antibiotics, and environment ...
Xuan Zhang   +6 more
wiley   +1 more source

Epigenetic Priming with Oral Decitabine/Cedazuridine Combined with Nivolumab in Unresectable or Metastatic Mucosal Melanoma: Clinical and Correlative Findings from a Phase Ib/II Trial. [PDF]

open access: yesCancers (Basel)
Borgers JSW   +13 more
europepmc   +1 more source

European Consortium for Lipodystrophies consensus definition and classification framework for monogenic lipodystrophy

open access: yesJournal of Internal Medicine, Volume 300, Issue 6, Page 725-742, December 2026.
Abstract Lipodystrophy comprises a heterogeneous group of disorders characterized by reduced adipose tissue often associated with severe metabolic complications. Lipodystrophy may be genetic, acquired, or secondary to medical therapies initiated for other conditions.
Robert K. Semple   +25 more
wiley   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2552-2561, 15 November 2026.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy